Floatz logo

Tcr Reserved And Power3 (Sppl3) Gene Knock-Out Allogeneic Cd19-Targeting Car-T Cell

Acute Lymphocytic Leukemia

Chinese PLA General HospitalCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

252 Active assets in the Acute Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BBB
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
Equine Atg
Instituto Nacional de Cancer, Brazil
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Tcr Reserved And Power3 (Sppl3) Gene Knock-Out Allogeneic Cd19-Targeting Car-T Cell is also rated in:

non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →